Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy
- 23 November 2004
- journal article
- review article
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 13 (2) , 85-96
- https://doi.org/10.1007/s00520-004-0699-x
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- Improved prevention of moderately emetogenic chemotherapy‐induced nausea and vomiting with palonosetron, a pharmacologically novel 5‐HT3 receptor antagonistCancer, 2003
- Delayed emesis: incidence, pattern, prognostic factors and optimal treatmentSupportive Care in Cancer, 2002
- Consensus proposal for 5HT 3 antagonists in the prevention of acute emesis related to highly emetogenic chemotherapySupportive Care in Cancer, 1998
- New perspectives in antiemetic treatmentSupportive Care in Cancer, 1996
- Is Navoban® (tropisetron) as effective as Zofran® (ondansetron) in cisplatin-induced emesis?Anti-Cancer Drugs, 1995
- Delayed emesis following high-dose cisplatin: A double-blind randomised comparative trial of ondansetron (GR 38032F) versus placeboEuropean Journal Of Cancer, 1993
- Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patientsEuropean Journal Of Cancer, 1992
- Ondansetron Compared with Metoclopramide in the Control of Emesis and Quality of Life during Repeated Chemotherapy for Breast CancerOncology, 1992
- Comparison of the 5-Hydroxytryptamine3(Serotonin) Antagonist Ondansetron (Gr 38032F) with High-Dose Metoclopramide in the Control of Cisplatin-Induced EmesisNew England Journal of Medicine, 1990
- The biological significance of soluble interleukin-2 receptors in solid tumorsEuropean Journal of Cancer and Clinical Oncology, 1990